Discovery of N-aryl sulphonamide-quinazoline derivatives as anti-gastric cancer agents in vitro and in vivo via activating the Hippo signalling pathway

Hippo signalling pathway plays a crucial role in tumorigenesis and cancer progression. In this work, we identified an N-aryl sulphonamide-quinazoline derivative, compound 9i as an anti-gastric cancer agent, which exhibited potent antiproliferative ability with IC50 values of 0.36 μM (MGC-803 cells),...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin-Bo Niu (Author), Chun-Hua Quan (Author), Yuan Liu (Author), Guang-Xi Yu (Author), Jia-Jia Yang (Author), Yin-Ru Li (Author), Yan-Bing Zhang (Author), Ying-Qiu Qi (Author), Jian Song (Author), Cheng-Yun Jin (Author), Sai-Yang Zhang (Author)
Format: Book
Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8ef17c5ecd874c5ebebd48e3d50c3f93
042 |a dc 
100 1 0 |a Jin-Bo Niu  |e author 
700 1 0 |a Chun-Hua Quan  |e author 
700 1 0 |a Yuan Liu  |e author 
700 1 0 |a Guang-Xi Yu  |e author 
700 1 0 |a Jia-Jia Yang  |e author 
700 1 0 |a Yin-Ru Li  |e author 
700 1 0 |a Yan-Bing Zhang  |e author 
700 1 0 |a Ying-Qiu Qi  |e author 
700 1 0 |a Jian Song  |e author 
700 1 0 |a Cheng-Yun Jin  |e author 
700 1 0 |a Sai-Yang Zhang  |e author 
245 0 0 |a Discovery of N-aryl sulphonamide-quinazoline derivatives as anti-gastric cancer agents in vitro and in vivo via activating the Hippo signalling pathway 
260 |b Taylor & Francis Group,   |c 2021-01-01T00:00:00Z. 
500 |a 1475-6366 
500 |a 1475-6374 
500 |a 10.1080/14756366.2021.1958211 
520 |a Hippo signalling pathway plays a crucial role in tumorigenesis and cancer progression. In this work, we identified an N-aryl sulphonamide-quinazoline derivative, compound 9i as an anti-gastric cancer agent, which exhibited potent antiproliferative ability with IC50 values of 0.36 μM (MGC-803 cells), 0.70 μM (HCT-116 cells), 1.04 μM (PC-3 cells), and 0.81 μM (MCF-7 cells), respectively and inhibited YAP activity by the activation of p-LATS. Compound 9i was effective in suppressing MGC-803 xenograft tumour growth in nude mice without obvious toxicity and significantly down-regulated the expression of YAP in vivo. Compound 9i arrested cells in the G2/M phase, induced intrinsic apoptosis, and inhibited cell colony formation in MGC-803 and SGC-7901 cells. Therefore, compound 9i is to be reported as an anti-gastric cancer agent via activating the Hippo signalling pathway and might help foster a new strategy for the cancer treatment by activating the Hippo signalling pathway regulatory function to inhibit the activity of YAP. 
546 |a EN 
690 |a hippo signalling pathway 
690 |a yap 
690 |a n-aryl sulphonamide-quinazoline 
690 |a anti-proliferative activity 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 36, Iss 1, Pp 1715-1731 (2021) 
787 0 |n http://dx.doi.org/10.1080/14756366.2021.1958211 
787 0 |n https://doaj.org/toc/1475-6366 
787 0 |n https://doaj.org/toc/1475-6374 
856 4 1 |u https://doaj.org/article/8ef17c5ecd874c5ebebd48e3d50c3f93  |z Connect to this object online.